Safety and Immunogenicity of the α-Synuclein Active Immunotherapeutic PD01A in Parkinson Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of the α-Synuclein Active Immunotherapeutic PD01A in Patients With Parkinson's Disease: A Randomised, Single-Blinded, Phase 1 Trial
Lancet Neurol 2020 Jul 01;19(7)591-600, D Volc, W Poewe, A Kutzelnigg, P Lührs, C Thun-Hohenstein, A Schneeberger, G Galabova, N Majbour, N Vaikath, O El-Agnaf, D Winter, E Mihailovska, A Mairhofer, C Schwenke, G Staffler, R MedoriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.